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Abstract
Background—Hypertension is a leading risk factor for cardiovascular disease. While control 
rates have improved over time, racial/ethnic disparities in hypertension control persist. Self-blood 
pressure monitoring (SBPM), by itself, has been shown to be an effective tool in predominantly 
white populations, but less studied in minority, urban communities. These types of minimally 
intensive approaches are important to test in all populations, especially those experiencing related 
health disparities, for broad implementation with limited resources.
Methods and Results—The New York City Health Department in partnership with community 
clinic networks implemented a randomized clinical trial (n=900, 450 per arm) to investigate the 
effectiveness of SBPM in medically underserved, and largely black and Hispanic participants. 
Intervention participants received a home blood pressure (BP) monitor and training on use, while 
control participants received usual care. After 9 months, systolic BP decreased (intervention: 14.7 
mm Hg, control: 14.1 mm Hg; p=0.70). Similar results were observed when incorporating 
longitudinal data and calculating a mean slope over time. Control was achieved in 38.9% of 
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intervention and 39.1% of control participants at the end of follow-up; the time-to-event 
experience of achieving BP control in the intervention vs. control were not different from each 
other (logrank p-value=0.91).
Conclusions—SBPM was not shown to improve control over usual care in this largely minority, 
urban population. The patient population in this study, which included a high proportion of 
Hispanics and uninsured persons is understudied. Results indicate these groups may have 
additional meaningful barriers to achieving BP control beyond access to the monitor itself.
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Introduction
Hypertension (HTN) is a major risk factor for cardiovascular disease (CVD), and yet 
nationally, only 69% of all individuals with HTN treated with anti-hypertensive medications 
meet treatment targets.1 HTN control has been shown to be lower in non-Hispanic blacks 
compared to non-Hispanic whites, while results are mixed in Hispanic populations vs. 
whites.2-4 CVD risk increases with even small increases in blood pressure (BP), thus 
establishing treatment and control of HTN as a significant public health priority.
Approaches to disease management aimed at increasing HTN control include the use of self-
blood pressure monitoring (SBPM).5 Although the precise mechanism through which it 
enhances control is not clearly defined, it is hypothesized that SBPM is effective because it 
increases patient awareness leading to healthier behaviors, and/or induces healthcare 
providers to advance therapy more actively.6-10 National interest in SBPM is increasing, as 
demonstrated by the recent release of an action guide developed by the Centers for Disease 
Control and Prevention (CDC) to support the Million Hearts initiative.11
SBPM has been shown to be an effective tool in reducing BP and improving HTN control, 
especially when enhanced with additional, non-treatment related supports such as 
educational materials or calls from nurses or pharmacists; however, the bulk of the literature 
on SBPM has focused on whites only.12, 13 Studies evaluating the effectiveness of SBPM in 
different racial and ethnic minority groups in urban, low income populations are few. A 
review by the Agency for Healthcare Research and Quality (AHRQ) on the effectiveness of 
SBPM was conducted contemporaneously with this study, and cited that small samples of 
race/ethnic subgroups in reviewed studies precluded any specific conclusions for these 
groups.14
In 2006, the New York City Health Department implemented an SBPM program in 19 
clinics in medically underserved neighborhoods where the majority (86%) of participants 
were black or Hispanic. Enrolled participants with uncontrolled HTN received BP monitors 
and training on how to use them. Evaluation of this program using a pre-post study design 
showed that fifty percent of participants achieved BP control at the end of 9 months.15 The 
desire to corroborate these results using a more rigorous study design (i.e., presence of a 
control group) led to the conduct of a randomized clinical trial by the Health Department 
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and clinical partners in 2010-11. The objective of the study was to assess if SBPM alone was 
effective in reducing elevated BP and in increasing HTN control in black and Hispanic 
patients from low income neighborhoods. Additionally, this study highlights the electronic 
health record (EHR) as a valuable tool for translational research.
Methods
The study design was a randomized clinical trial conducted in a large heath center network 
(six sites) and two small, independent community health centers (one site each), for a total 
of eight clinic sites. These sites treat populations that are medically underserved; the large 
network which included six sites and one of the smaller centers were federally qualified 
health centers (FQHC). The design and implementation of this study incorporated aspects of 
participatory action research16 in that it was a collaborative effort between the Health 
Department and community clinic networks. The healthcare networks were using the same 
EHR, eClinicalWorks, and receiving technical assistance on systems changes from Health 
Department staff. All eClinicalWorks practices have BP quality and decision support 
measures that allow for monitoring of their patient populations. The trial consisted of two 
study arms: an intervention arm where participants received automatic home BP monitors 
with modems capable of transmitting (or “uploading”) home BP readings via phone line to a 
secure database for evaluation, and a control arm where participants received usual care. The 
DOHMH collaborated with iMetrikus/Numera to provide a mechanism for uploading and 
collecting the participants’ home readings.
The target sample size for enrollment was 996, or 498 participants in each arm. This would 
have allowed for the detection of a 3.3 mm Hg (SD: 17 mm Hg) difference in systolic BP 
between intervention and control arms after 9 months at 80% power, and 99.8% power to 
detect BP control over time using time-to-event analysis, both accounting for study 
participant attrition (13.6% over 9 months). The original study design sought to recruit 
Hispanics, non-Hispanic blacks, and non-Hispanic whites evenly (33% of study sample of 
each race/ethnicity) using stratified, block randomization. With even distribution of study 
arms across three race/ethnic groups (n=165 per arm, per race/ethnicity), a difference of 5.7 
mm Hg in systolic BP would be detectable within race/ethnic group; detection of BP control 
over time using time-to-event analysis was powered at 80%. In the planning process, study 
sites were selected based on having sufficient information technology (IT) infrastructure and 
provider interest which limited the demographics of the final recruited sample. The 
percentage of Hispanics was 62%, blacks 28%, and whites 10%. Between race/ethnic 
comparisons (e.g., Hispanic vs. white) were not performed given limited sample size.
Participant Recruitment and Randomization with the Electronic Health Record
Participants needed to meet all eligibility criteria: a) age 18 years or older; b) diagnosis of 
HTN for at least 6 months; c) last visit BP uncontrolled (systolic BP ≥ 140 mm Hg or 
diastolic BP ≥ 90 mm Hg; for those with diabetes or chronic kidney disease [CKD]: systolic 
BP ≥ 130 mm Hg or diastolic BP ≥ 80 mm Hg); d) not currently measuring BP at home; e) 
access to a land [telephone] line; f) Hispanic, black or white; g) capacity to use the home 
monitor and record readings as determined by the provider; and h) current visit BP 
Yi et al. Page 3
Circ Cardiovasc Qual Outcomes. Author manuscript; available in PMC 2015 March 19.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
uncontrolled. Criteria ‘a’ through‘c’ were built into the EHR, such that only those who met 
those criteria were approached and screened for the study. All other criteria were assessed 
by a smartform, as described below.
Participants’ eligibility was determined and participants were automatically randomized into 
the intervention or control group by a smartform, a software tool residing within the EHR. 
The study smartform was developed by Health Department staff in collaboration with the 
EHR vendor for use in this study. The smartform is a tool that provides a method of query-
able structured data collection and performs basic study logic and calculations. While some 
providers had used similar smartforms in the past to collect patient histories for depression/
smoking, providers and non-provider/nursing staff at participating clinics did receive some 
training to become familiar and comfortable with the new smartform and the workflow that 
it entailed.
Patients were enrolled from June 7, 2010 thru October 7, 2011. A typical screening 
workflow proceeded in the following manner. After the vital signs were taken by the 
medical assistant, the smartform was opened and pre-populated with the study protocol and 
relevant patient information (eligibility criteria a-c listed above). If the patient met the initial 
eligibility criteria, the nurse continued the screening by asking the first 5 questions on the 
smartform (screenshot of smartform is included in the Supplementary Appendix online; 
included assessment of whether the patient was willing to be screened, and eligibility criteria 
d-f). If the patient was still eligible, when the patient saw the provider, the provider would 
answer the next three questions on the form (eligibility criteria g-h; and verification of CKD 
or diabetes diagnoses). If all three answers were yes, the patient was sent back to the nurse 
to complete enrollment including obtaining consent, randomization by answering “yes” to 
the last question, and training if in the intervention arm. The information from the smartform 
was passed to an integrated study protocol EHR module responsible for enrolling a 
randomized and balanced cohort of patients for each race/ethnicity for each control/
intervention arm. All patients screened and enrolled in the study were tracked in a master 
study participants table within the EHR database, which prevented duplicate enrollments 
and facilitated study data collection efforts throughout the program. The screening and 
consent process was adapted to fit each clinic setting to minimize changes to workflow.
After randomization, participants in both arms were asked to return to the clinic as per their 
regularly scheduled visits. Intervention arm participants received BP monitors, educational 
materials on HTN, and a tote bag. They were trained on how to use their monitors, record 
their BP, and upload their home readings (transmitting them electronically to the secured 
database), and were encouraged to share their BP readings with their doctors. Control arm 
participants received usual care, and as an incentive, a BP monitor at the end of study 
follow-up. The planned follow-up period was 9 months, longer than the majority of previous 
studies on SBPM13 to demonstrate persistence and maintenance of improvement over time. 
The Institutional Review Board of each participating institution approved this study; 
informed consent from the patient was required to participate in the trial.
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Data and Variable Definitions
Clinic data for analysis was pulled from the EHRs in all clinic sites with the assistance of 
Health Department staff and the clinic IT staff in September and October 2012. Data 
included demographic characteristics (age at baseline, sex, race/ethnicity, nativity, body 
mass index [BMI], primary insurance [self-pay, Medicare, other]), systolic and diastolic BP 
at each clinic visit, and mean number of clinic visits (defined as having a clinic BP reading 
in the EHR). Clinic BP values were those BP readings that were taken at the start of the 
clinic visit as a part of vital signs measurements, and were pulled from this field in the EHR. 
Given the applied design of this trial, a clinic visit specifically for the study was not 
required. Nativity was defined as U.S. born or foreign born; those born in Puerto Rico were 
categorized as U.S. born since they are more likely to have health insurance, 17 potentially 
owing to their U.S. citizenship status. Relevant comorbidities (diabetes diagnosis, CKD 
diagnosis, personal history of heart disease and of stroke) were assessed using corresponding 
International Classification of Disease (ninth edition, ICD-09) codes for each condition 
(diabetes: 250; CKD: 585; heart disease: 393-398, 402, 404-429; stroke: 430-438 (but not 
435)).
Outcomes assessed were change in systolic and diastolic BP from baseline to follow-up, the 
slope of BP over the follow-up period including all available BP measurements, and 
achievement of BP control. Control was defined as systolic BP <140 mm Hg and diastolic 
BP <90 mm Hg (<130/80 for those with diabetes or CKD). Because participants were not 
asked to come back specifically for this study but according to the clinic’s regular schedule 
of follow-up visits for patients with HTN, the window for a follow-up visit was defined as a 
range of 7-10 months. Follow-up was enumerated in two ways. First, any participant who 
had at least one BP measurement during the 10 month follow-up time was enumerated as 
having at least one follow-up visit, and was included in analyses of change in BP slope and 
in the time-to-event (achieving BP control) analyses. Second, a participant who had at least 
one visit in the 7-10 month interval was included in analyses of change in baseline to 
follow-up BP comparisons; the first value in the 7-10 month interval was used. Specific 
participant flow is described in the Results below.
Analytic Methods
Participant characteristics at baseline were compared between the intervention and control 
groups, and stratified by race/ethnicity to verify comparability of the two study arms. 
Differences were assessed using t-test and the Wilcoxon Rank Sum test for normal and non-
normal continuous variables respectively, and the chi-square test and Fisher’s exact test for 
categorical variables.
Owing to the multi-site nature of the study design, the strength of clustering and the degree 
of dependence was measured by the intra-cluster correlation coefficient (ICC). The ICCs 
showed some, albeit minor, statistically significant evidence of hierarchical clustering of 
individuals within sites (ICC=0.03, p<0.001 for systolic BP, 0.05, p<0.001for diastolic BP). 
Therefore, changes in systolic and diastolic BP were assessed by intervention group, by 
race/ethnicity, and by home upload status, and were compared using multi-level linear 
mixed models with one between subjects factor (intervention group – intervention vs. 
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control) and one within-subjects factor (time – baseline and follow-up) accounting for non-
independence and correlation of the BP measurements within patients and hierarchical 
clustering of patients within clinic sites. The change in BP measurements from baseline to 
follow-up was directly measured by the group x time interaction term within each 
intervention group and then compared between the two intervention groups. Separate 
models were developed for systolic BP and diastolic BP. Several residual covariance 
structures were tested by using likelihood ratio test (LRT), the Akaike’s Information 
Criterion (AIC) and Bayesian Information Criterion (BIC) measures and models with an 
unstructured correlation structure showed to be the best fitted models.
Since the clustering effect in our data was unintentional and not an explicit part of the study 
design, a secondary sensitivity analysis was conducted by using an alternative simpler 
approach of analysis of covariance on BP change (follow-up – baseline measurements) 
controlling for the baseline BP measurements ignoring the hierarchical site clustering effect. 
Separate models were developed for systolic BP and diastolic BP. This sensitivity analysis 
however, produced similar inferences to the mixed model approach for the level of statistical 
significance of change in BP between the study groups and thus for brevity, are not included 
in this report.
The slopes of BP over the follow-up period were calculated and compared using random 
coefficient models accounting for the longitudinal correlation of BP measurements within 
patients, overall and by race/ethnicity. Percent achieving control in the study period was 
assessed using time-to-event analysis, overall and by race/ethnicity. The comparison of 
interest was the time (months) that it took the intervention and control groups to achieving 
BP control for the first time. Differences in the time-to-event experience were compared 
using the Kaplan-Meier survival distribution function, survival curves, and log-rank tests.
To assess whether frequency of BP measurements at home impacted clinic results in the 
intervention group, intervention arm participants were additionally stratified by whether or 
not they uploaded their home readings. This pre-specified analysis was performed to 
determine best patterns of home BP monitor use. Intervention-uploaders were defined as 
intervention arm participants who uploaded (n=182); intervention-non-uploaders were 
defined as intervention arm participants who did not upload (n=224). Intervention-uploaders 
were stratified as measuring BP 2+ times/day (n=96) or <2 times/day (n=86); this cutoff was 
decided post hoc based on the distribution of the data.
All statistical analyses were conducted using SAS software version 9.2 (SAS Institute, Inc., 
Cary, North Carolina).
Results
Ninety-one percent (409) of intervention and 93% (419) of control participants had a 
baseline visit and at least one follow-up visit within 10 months, which meant they were 
included in the analysis of BP slope over time, and the time-to-event analysis. Seventy-three 
percent (329) in the intervention group and 74% (332) in the control group had a follow-up 
visit in the 7 to 10 months follow-up window only; analyses of change from baseline to 
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follow-up BP included only these individuals. A participant flow diagram, which also 
includes the breakdowns by race/ethnicity, is displayed in Figure 1. The median number of 
visits per participant was 5 (IQR: 3-8 visits) in both study arms. The majority of the study 
population was female (68%); Hispanic (63%); foreign born (51%); had diabetes (59%); and 
were self-pay/uninsured (69%). Characteristics of participants by interventions arm are 
displayed in Table 1. The intervention and control groups were similar with respect to age, 
sex, race/ethnicity, nativity, BMI, diabetes, CKD, personal history of heart disease and 
stroke, and primary insurance. Diastolic BP at baseline was slightly higher in the 
intervention vs. control group (83.9 ± 11.2 mm Hg vs. 82.3 ± 10.6 mm Hg, p=0.04). No 
significant differences were found between intervention arms by race/ethnicity (results not 
shown), other than a higher prevalence of diabetes among black participants in the 
intervention (60.4%) vs. control group (43.9%, p=0.02). Additionally, whites in the 
intervention group had a higher mean systolic BP at baseline compared to the white control 
group (157.7 ± 16.6 mm Hg vs. 150.8 ± 14.2 mm Hg, p=0.04).
Mean systolic and diastolic BP at baseline and follow-up, and changes in values are 
displayed in Table 2. Overall, systolic BP decreased 14.7 mm Hg (p<0.001) in the 
intervention group and 14.1 mm Hg (p<0.001) in the control group, with no significant 
difference between these decreases (p=0.70). When stratified by race/ethnicity, the 
difference in systolic BP decrease was significant in white participants only (p=0.01), and 
not in blacks (p=0.95) or Hispanics (p=0.56). Similar results were observed with diastolic 
BP values, with the only significant effect of the intervention being observed in whites. 
There was no difference in the slope over the follow-up period between the intervention and 
control groups (Table 2), but again, differences were apparent in the whites only.
BP control was achieved in 38.9% of intervention and 39.1% of control participants after 10 
months, though the time-to-event experience of intervention vs. control were not different 
from each other (logrank p-value=0.91; Figure 2). Achieving BP control did not differ for 
intervention vs. control for any of the race/ethnic groups (logrank p-values: whites p=0.50, 
Blacks p=0.11, Hispanics p=0.64).
Home Data Results
Overall, those in the intervention group who uploaded their readings (uploaders) and those 
who did not upload their readings (non-uploaders) were similar to each other on key 
demographic characteristics, including age, sex, race/ethnicity, nativity, BMI, diabetes, 
CKD, history of CVD and insurance status. When considering uploaders only, uploaders 
who took BP measurements >2 times per day were more likely to achieve BP control in the 
clinic compared to uploaders who took BP measurements >2 times per day (log rank p-value 
= 0.02); and had a larger change systolic BP over time (decrease in uploaders: >2 times/
day=1.06 mm Hg; <2 times/day=0.48 mm Hg, p=0.05). When comparing intervention – 
uploaders, intervention – non-uploaders, and control, there were no differences in achieving 
BP control (log rank p-value = 0.38) or in slope over time.
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Discussion
Overall, the distribution of self BP monitors was not shown to be more effective in reducing 
BP over time or in improving BP control above and beyond usual care in this largely 
minority sample of NYC adults from medically underserved communities. The intervention 
was not found to be effective among Hispanic and black participants for any BP outcomes. 
It was effective among white participants in reducing BP compared to the control group, but 
not in achieving control over time. The participants in this study represent a unique subset of 
individuals typically understudied in the literature: predominantly Hispanic (~70%); foreign 
born (~60%); and uninsured or self-pay patients (~70%). While the recent studies include 
emerging information on predictors or correlates of BP control in Hispanics,3, 4, 18, 19 to our 
knowledge, this is one of first randomized clinical trials to evaluate SBPM in an urban, 
medically underserved population. Consistent with the AHRQ review published January 
2012 on the effectiveness of SBPM, we conclude that SBPM alone was not effective in our 
study sample under existing conditions.
In both the intervention and control groups, BP reductions corroborate the magnitude of BP 
reduction observed in the evaluation of the SBPM program, where we observed an 18.7 mm 
Hg reduction in systolic BP and a 8.5 mm Hg reduction in diastolic BP using a pre-post 
design (systolic BP 9.0 mm Hg reduction, diastolic BP 3.4 mm Hg reduction after 
adjustment for regression to the mean).15 However in the current study, the magnitude of the 
effect in the intervention group was not greater than the effect observed in the control group. 
Because this study was randomized at the participant level and not the provider or practice 
level, providers may have been engaging with participants in both the intervention and 
control arms similarly with respect to activities around BP control. As a part of EHR 
implementation, the Health Department provided technical assistance and all 
eClinicalWorks practices had enhanced BP quality and decision support measures that 
allowed for monitoring of their patient populations. Further, the clinic network from which 
our largest percentage (85%) of participants came from additionally was able to achieve 
Level 3 status as a Patient Centered Medical Home (in part due to their participation in the 
current study). These activities included improvements in BP measurements through training 
of medical assistants on appropriate cuff sizes and increased education on BP generally 
among nurses. This may partially explain the large decrease observed in the control group as 
this may have impacted usual care. Additionally, it may be that simply enrolling in the 
study, with or without the BP monitor may have been a factor in some participants being 
able to lower their BP and achieve BP control.
The high percentage of uninsured participants bears implication on interpretation of the 
study results. Lack of insurance has been shown to be associated with lower rates of BP 
control20, 21 owing in part to decreased regular access to BP medications, or lower access to 
BP monitoring.21 Prior studies have demonstrated less use of a BP monitor in lower income 
groups,22, 23 providing evidence that the cost of the monitor may be a meaningful barrier to 
use. Through our study design, participants had access to a BP monitor, but facilitated 
access to other resources related to BP management such as behavioral counseling above 
and beyond what is provided by the clinic staff or reduced cost medications, was not 
provided. Therefore in this patient population with a high prevalence of being uninsured, 
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supplying the BP monitor itself may not be sufficient to produce the anticipated benefits in 
BP outcomes.
By enrolling those who are both uninsured and foreign born, we may have captured a 
population that is known to have additional barriers such as reduced communication with 
their provider or restrictions in access to other health resources. Further, it has been 
suggested that Hispanics are less likely than whites or non-Hispanic blacks to benefit from 
community interventions targeting hypertension owing in part to barriers to access to care 
and treatment, dietary patterns, acculturation levels, and communication barriers.18 Thus it 
may be that the dissemination of SBPM in this population should be accompanied by 
additional support services which might include education, appropriate language support, 
and cultural tailoring for achieving BP control. This should be a topic of further study.
Few studies to date have explored patient-related patterns of home use, and the optimal 
schedule for readings using a home monitor.24, 25 We collected and evaluated home data to 
address this limitation in the current literature, and found that those who were measuring 
their BP 2+ times/day vs. <2 times/day were more likely to achieve BP control. However 
our small sample size limits the conclusions that can be made from these results. Another 
interesting finding is that only one half of those who received monitors actually engaged in 
uploading information, even with the additional support provided through participation in 
this research study. In this current era of expanding the use of technology in medical care, 
much attention has been given to the idea of efficiently increasing provider reach to patients 
in between office visits through the remote uploading of patient information. Our study 
suggests that the practical realities of this strategy in populations such as ours should be 
carefully considered.
There are several strengths worth highlighting in our study design. The innovative use of the 
smartform to screen eligible patients and to randomize to treatment arms minimized bias on 
the part of the provider. To our knowledge, this is one of the first studies to utilize this 
mechanism. Further, the EHR enabled us to collect systematic, longitudinal data on all study 
participants, including detailed data on comorbidities such as diabetes, CKD, and a detailed 
assessment of past history of CVD through ICD codes in the EHR rather than self-report. 
Lastly, we leveraged existing electronic systems and relationships to maximize efficiency in 
study conduct; factors strongly indicated by national institutions for cardiovascular disease 
research.26
In terms of limitations, there may have been bias operating at the study site level. At the 
largest study site the BP-related quality improvements described above were being 
implemented, which may have influenced the control group. A second limitation was that 
medication data for our largest study site was irretrievable. Therefore any behaviors related 
to medication intensification by the providers or whether the medication intensification had 
an impact on the results were not assessed. Third, we were unable to assess whether 
participants understood their readings and/or incorporated self-monitoring into their daily 
routines. While we assessed this in the focus groups and embedded a question on BP 
readings in the EHR, both modalities yielded low compliance and are thus not reported on in 
the current manuscript. Fourth, any potential differences in the frequency of BP 
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measurements between the intervention and control groups could have led to differing 
probabilities of control by chance alone; however this seems to have had a minimal effect to 
current results. Lastly, the small sample size of whites in this study limit the conclusions that 
can be made in this race/ethnic subgroup, in addition to the significantly higher baseline 
systolic BP in whites in the intervention vs. control group.
The SBPM intervention was not found to be impactful on lowering BP beyond usual care in 
this study population composed primarily of Hispanics, foreign born individuals and those 
who lacked insurance, as has been observed in predominantly white populations. While 
SBPM may be effective in some populations, it did not appear to have a meaningful impact 
under the conditions of the current study. In settings where a number of quality 
improvement activities are occurring, any improvements that may be observed by the 
provision of a BP monitor by itself (i.e., low-level intervention) may not be observable. We 
view these results as a starting point for expanding current strategies on BP control in 
specific subgroups, as an example of collaborative applied clinical research, and as a model 
for efficient study design and methods utilizing the EHR.
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Figure 1. 
Study Participant Flow Diagram
*Estimated values based on prior data pull. Final data was irretrievable.
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Figure 2. 
Survival Curves for Time to Control, Intervention and Control Arms
*Blood pressure control defined as systolic blood pressure <140 and diastolic blood pressure 
<90 mm Hg; systolic blood pressure<130 and diastolic blood pressure <80 mm Hg for those 
with diabetes or kidney disease
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Table 1
Study Participants Characteristics by Intervention Group
Characteristic Intervention (n=409) Control (n=419) p-value
Age at Baseline, mean ± SD 61.3 ± 11.9 61.3 ± 12.2 0.98
Female Sex, n (%) 275 (67.2) 285 (68.0) 0.81
Race, n (%)
 Non-Hispanic White 43 (10.5) 44 (10.5) 0.87
 Non-Hispanic Black 111 (27.1) 107 (25.5)
 Hispanic 255 (62.4) 268 (64.0)
Country of Birth, n (%)*
 US Born 134 (35.9) 108 (37.4) 0.70
 Foreign Born 239 (64.1) 181 (62.6)
BMI, kg/m2, n (%)
 Normal, 18.5-<25 57 (14.1) 48 (11.6) 0.51
 Overweight, 25-<30 123 (30.4) 136 (32.9)
 Obese, 30+ 225 (55.6) 230 (55.6)
Diabetes Diagnosis, n (%) 255 (62.4) 235 (56.1) 0.07
Chronic Kidney Disease Diagnosis, n (%) 12 (2.9) 11 (2.6) 0.79
Personal History of Heart Disease, n (%) 115 (28.1) 138 (32.9) 0.13
Personal History of Stroke, n (%) 53 (13.0) 57 (13.6) 0.78
Primary Insurance, n (%)
 Self-Pay 283 (69.2) 289 (69.0) 0.84
 Medicare 18 (4.4) 22 (5.3)
 Other 108 (26.4) 108 (25.8)
Systolic BP at baseline, mean ± SD* 151.5 ± 16.4 152.1 ± 15.0 0.58
Diastolic BP at baseline, mean ± SD* 83.9 ± 11.2 82.3 ± 10.6 0.04
# of visits, median (25-75% IQR) 5 (3-8) 5 (3-8) 0.65
Abbreviations: SD – standard deviation, BP – blood pressure, IQR – interquartile range
*Values here are not adjusted for clustering and thus differ from BP mean change analyses displayed in Table 2
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